Absolute neutrophil count during the course of treatment.
(1) The patient received chemomobilization therapy with rituximab 375 mg/m2, days −54 and −47, cyclophosphamide 4 g/m2 intravenously, day −52, mesna 1.33 g/m2, thrice a day on day −52, etoposide 200 mg/m2 intravenously on days −52 to −50, and dexa-methasone 10 mg orally four times a day, day −52 to −49. (2) Peripheral blood stem cell collection. (3) Autologous transplant following 12 Gy of linear accelerator radiation, etoposide 60 mg/kg, and cyclophosphamide 100 mg/kg. (4) Posttransplantation rituximab (375 mg/m2 ) was given on days +30 and +37. (5) GCSF 480 μg/day beginning on day +130 and doubled on day +134. (6) Two doses of intravenous immunoglobulin (IVIG). (7) GM-CSF, 250 μg/m2/day. (8) Cyclosporine 200 mg orally twice a day, tapered ultimately to 50 mg orally twice a day.
